Advertisement

CardioVascular and Interventional Radiology

, Volume 41, Issue 11, pp 1743–1750 | Cite as

Image-Guided Thermal Ablation for Non-resectable Recurrence of Renal Cell Cancer Following Nephrectomy: Clinical Experience with Eleven Patients

  • Wenhui Zhou
  • Sanna E. Herwald
  • Raul N. Uppot
  • Ronald S. Arellano
Clinical Investigation
  • 75 Downloads

Abstract

Purpose

To assess the feasibility, safety and clinical outcomes of image-guided percutaneous thermal ablation as salvage therapy for local recurrence of renal cell carcinoma (RCC) in patients initially treated surgically with curative intent.

Materials and Methods

A retrospective review of 11 consecutive patients (M/F = 8:3, mean age = 76 years) who underwent computed tomography (CT)-guided thermal ablation for locally recurrent RCC after partial (72%, 8/11) or radical nephrectomy (28%, 3/11) with a mean time to recurrence of 48 months (range 2–156). Assessment of technical success, complication (peri- and post-procedural), oncological outcome and survival analysis were performed. Patient baseline and follow-up renal function surrogates including creatinine level (Cr) and estimated glomerular filtration rate (eGFR) were statistically compared.

Results

Eleven biopsy-proven recurrent RCC measuring 1.4–3.9 cm (mean = 2.8 cm) were treated with CT-guided thermal ablation. Technical success was achieved in 100% (11/11) of the cases. There were no major complications except for one (9%) asymptomatic hemorrhage (Clavien–Dindo grade I complication). Complete response, local progression-free and overall survival rate were 91, 91 and 82% during the mean follow-up time of 2.5 years (range 0.1–7.1). Renal function was overall stable without significant change at 1 month and last follow-up (p = 0.21; GFR, p = 0.10; creatinine).

Conclusions

Image-guided percutaneous thermal ablation is a feasible, safe and effective for local recurrence after nephrectomy, representing a non-surgical alternative for unresectable disease.

Keywords

Thermal ablation Recurrent RCC Salvage therapy Nephrectomy 

Notes

Compliance with Ethical Standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.CrossRefGoogle Scholar
  2. 2.
    Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.CrossRefGoogle Scholar
  3. 3.
    Bratslavsky G, Linehan WM. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol. 2010;7(5):267–75.CrossRefGoogle Scholar
  4. 4.
    Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol. 2008;180(1):89–93 (discussion).CrossRefGoogle Scholar
  5. 5.
    Sandhu SS, Symes A, A’Hern R, Sohaib SA, Eisen T, Gore M, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int. 2005;95(4):522–5.CrossRefGoogle Scholar
  6. 6.
    Master VA, Gottschalk AR, Kane C, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol. 2005;174(2):473–7 (discussion 7).CrossRefGoogle Scholar
  7. 7.
    Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB, et al. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU Int. 2017;119(1):116–27.CrossRefGoogle Scholar
  8. 8.
    Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.CrossRefGoogle Scholar
  9. 9.
    Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67(2):252–9.CrossRefGoogle Scholar
  10. 10.
    Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol. 2012;61(6):1156–61.CrossRefGoogle Scholar
  11. 11.
    Wehrenberg-Klee E, Clark TW, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, et al. Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol. 2012;23(1):41–5.CrossRefGoogle Scholar
  12. 12.
    Arellano RS, Garcia RG, Gervais DA, Mueller PR. Percutaneous CT-guided radiofrequency ablation of renal cell carcinoma: efficacy of organ displacement by injection of 5% dextrose in water into the retroperitoneum. Am J Roentgenol. 2009;193(6):1686–90.CrossRefGoogle Scholar
  13. 13.
    Cantwell CP, Wah TM, Gervais DA, Eisner BH, Arellano R, Uppot RN, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol. 2008;19(7):1034–40.CrossRefGoogle Scholar
  14. 14.
    McLaughlin CA, Chen MY, Torti FM, Hall MC, Zagoria RJ. Technical innovation—radiofrequency ablation of isolated local recurrence of renal cell carcinoma after radical nephrectomy. Am J Roentgenol. 2003;181(1):93–4.CrossRefGoogle Scholar
  15. 15.
    Monfardini L, Varano GM, Foa R, Della Vigna P, Bonomo G, Orsi F. Local recurrence of renal cancer after surgery: prime time for percutaneous thermal ablation? Cardiovasc Interv Radiol. 2015;38(6):1542–7.CrossRefGoogle Scholar
  16. 16.
    Hegg RM, Schmit GD, Boorjian SA, McDonald RJ, Kurup AN, Weisbrod AJ, et al. Percutaneous renal cryoablation after partial nephrectomy: technical feasibility, complications and outcomes. J Urol. 2013;189(4):1243–8.CrossRefGoogle Scholar
  17. 17.
    Kochhar G, Mehta P, Kalra S, Singh G, Maurer W, Tetzlaff J, et al. Does the ASA physical status classification predict airway or cardiopulmonary complications during routine EGD or colonoscopy utilizing anesthesiologist-directed propofol sedation? A prospective cohort study. Am J Gastroenterol. 2012;107:S751.Google Scholar
  18. 18.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, et al. Toxicity and response criteria of the eastern-cooperative-oncology-group. Am J Clin Oncol Cancer. 1982;5(6):649–55.CrossRefGoogle Scholar
  19. 19.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications—a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefGoogle Scholar
  20. 20.
    Omary RA, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg MS, Sacks D, et al. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol. 2002;13(9):879–81.CrossRefGoogle Scholar
  21. 21.
    Thumar AB, Trabulsi EJ, Lallas CD, Brown DB. Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol. 2010;21(8):S233–41.CrossRefGoogle Scholar
  22. 22.
    Eisenhauer E, Therasse P, Bogaerls J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1. EJC. 2008;6(12):13.Google Scholar
  23. 23.
    Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164(2):322–5.CrossRefGoogle Scholar
  24. 24.
    Chow JJ, Ahmed K, Fazili Z, Sheikh M, Sheriff M. Solitary renal fossa recurrence of renal cell carcinoma after nephrectomy. Rev Urol. 2014;16(2):76–82.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Magera JS, Frank I, Lohse CM, Leibovich BC, Cheville JC, Blute ML. Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant. J Urol. 2008;179(3):853–6.CrossRefGoogle Scholar
  26. 26.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRefGoogle Scholar
  27. 27.
    Zhou WH, Uppot RN, Feldman AS, Arellano RS. Percutaneous image-guided thermal ablation for multifocal renal cell carcinoma: 10-year experience at a single center. Am J Roentgenol. 2017;209(4):733–9.CrossRefGoogle Scholar
  28. 28.
    Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, et al. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int. 2010;105(4):496–500.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  • Wenhui Zhou
    • 1
  • Sanna E. Herwald
    • 1
  • Raul N. Uppot
    • 2
  • Ronald S. Arellano
    • 2
  1. 1.Tufts University School of MedicineBostonUSA
  2. 2.Department of Radiology, Division of Interventional Radiology, Harvard Medical SchoolMassachusetts General HospitalBostonUSA

Personalised recommendations